Reported 1,318,983 shares, unchanged from the prior quarter.
Reported value -38.4%; share count 0.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2026-03-31 | 13954840 |
| 2026-06-30 | 17212728 |
| 2026-09-30 | 10604623 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Unchanged | 1,318,983 | 0 (0.0%) | 3.67% | $10,604,623 | 2026-11-16 | |
| Q2 2026 | Unchanged | 1,318,983 | 0 (0.0%) | 4.75% | $17,212,728 | 2026-08-14 | |
| Q1 2026 | New | 1,318,983 | +1,318,983 (0.0%) | 5.15% | $13,954,840 | 2026-05-15 |
Who else reported the position
107 managers reported EIKON THERAPEUTICS INC for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 5,520,152 | +526,246 | < 0.01% | $44,382,022 | 3 qtrs |
| BlackRock Inc | Added | 4,869,276 | +587,851 | < 0.01% | $39,148,980 | 3 qtrs |
| Foresite Capital Management IV LLC | Unchanged | 1,943,682 | 0 | 6.2% | $15,627,203 | 3 qtrs |
| Merck & Co Inc | Unchanged | 1,666,666 | 0 | 1.63% | $13,399,995 | 3 qtrs |
| T Rowe Price Investment Management Inc | Added | 1,637,441 | +42,167 | < 0.01% | $13,166,000 | 3 qtrs |
| Foresite Capital Management V LLC This report | Unchanged | 1,318,983 | 0 | 3.67% | $10,604,623 | 3 qtrs |
| Capital World Investors | Unchanged | 1,175,944 | 0 | < 0.01% | $9,454,590 | 3 qtrs |
| PRICE T ROWE ASSOCIATES INC MD | Added | 1,110,649 | +105,614 | < 0.01% | $8,931,000 | 3 qtrs |
| ALLIANCEBERNSTEIN L P | Added | 1,052,041 | +410,153 | < 0.01% | $8,458,410 | 3 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 1,015,513 | +92,806 | < 0.01% | $8,164,725 | 3 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 16, 2026
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 1,318,983
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.